ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2017
Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03840369 (Pathophysiological Understanding and Treatment of PTSD), which is not on this map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pathophysiological Understanding and Treatment of PTSD: an rTMS Approach
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- Exploring easily accessible neurophysiological biomarkers for predicting Alzheimer's disease progression: a systematic review.Alzheimer's research & therapy · 2024Pooled it
- The evolving role of surface electromyography in amyotrophic lateral sclerosis: A systematic review.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2020Pooled it
- Altered blood parameters in "major depression" patients receiving repetitive transcranial magnetic stimulation (rTMS) therapy: a randomized case-control study.Translational psychiatry · 2024Trial
- Cortical inhibition in neurofibromatosis type 1 is modulated by lovastatin, as demonstrated by a randomized, triple-blind, placebo-controlled clinical trial.Scientific reports · 2022Trial
- Coil Orientation in Transcranial Magnetic Stimulation Affects Motor-evoked Potential Size more than its Timing or Waveform Shape.Brain topography · 2026Article
- Acute adaptations to eccentric cycling and downhill walking: physiological and neuromuscular responses.European journal of applied physiology · 2026Article
- Delayed transcallosal conduction to the lesioned sensorimotor cortex in multiple Sclerosis: A combined TMS 7 T-MRI study.NeuroImage. Clinical · 2026Article
- Clinical development and guiding theory of transcranial magnetic stimulation: a literature review.Annals of medicine · 2025Review
- Feasibility of rTMS combined with dexmedetomidine in chronic insomnia disorder.Scientific reports · 2025Article
- Cell Type-Specific Alterations in Excitability and Inhibition of Upper Motor Neurons in AlsinKO Mice, a Model of Juvenile Onset ALS.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- Neurophysiologic Innovations in ALS: Enhancing Diagnosis, Monitoring, and Treatment Evaluation.Brain sciences · 2024Review
- Clinical features and progress in diagnosis and treatment of amyotrophic lateral sclerosis.Annals of medicine · 2024Review
- Dependence of cortical neuronal strength-duration properties on TMS pulse shape.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology · 2023Article
- Voltage-Gated Sodium Channel Dysfunctions in Neurological Disorders.Life (Basel, Switzerland) · 2023Review
- A cognitive task, deep breathing, and static stretching reduce variability of motor evoked potentials during subsequent transcranial magnetic stimulation.Brain research · 2023Article
- rTMS regulates homotopic functional connectivity in the SCD and MCI patients.Frontiers in neuroscience · 2023Article
- Sex-specific reference values for total, central, and peripheral latency of motor evoked potentials from a large cohort.Frontiers in human neuroscience · 2023Article
- Normal parameters for diagnostic transcranial magnetic stimulation using a parabolic coil with biphasic pulse stimulation.BMC neurology · 2022Article
- A Transmissive Theory of Brain Function: Implications for Health, Disease, and Consciousness.NeuroSci · 2022Article
- Toward noninvasive brain stimulation 2.0 in Alzheimer's disease.Ageing research reviews · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcranial magnetic stimulation (TMS) is a noninvasive technique that has provided important information about cortical function across an array of neurodegenerative disorders, including Alzheimer's disease, frontotemporal dementia, Parkinson's disease, and related extrapyramidal disorders. Application of TMS techniques in neurodegenerative diseases has provided important pathophysiological insights, leading to the development of pathogenic and diagnostic biomarkers that could be used in the clinical setting and therapeutic trials. Abnormalities of TMS outcome measures heralding cortical hyperexcitability, as evidenced by a reduction of short-interval intracortical inhibition and increased in motor-evoked potential amplitude, have been consistently identified as early and intrinsic features of amyotrophic lateral sclerosis (ALS), preceding and correlating with the ensuing neurodegeneration. Cortical hyperexcitability appears to form the pathogenic basis of ALS, mediated by trans-synaptic glutamate-mediated excitotoxic mechanisms. As a consequence of these research findings, TMS has been developed as a potential diagnostic biomarker, capable of identifying upper motor neuronal pathology, at earlier stages of the disease process, and thereby aiding in ALS diagnosis. Of further relevance, marked TMS abnormalities have been reported in other neurodegenerative diseases, which have varied from findings in ALS. With time and greater utilization by clinicians, TMS outcome measures may prove to be of utility in future therapeutic trial settings across the neurodegenerative disease spectrum, including the monitoring of neuroprotective, stem-cell, and genetic-based strategies, thereby enabling assessment of biological effectiveness at early stages of drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.